Biomedische wetenschappen


Meer informatie
° ASU20 Engels
Tags: safety pharmacology , drug development

INSPIRE offers an intensive 5-days programme with a particular focus on Cardiovascular Safety Pharmacology and Cardio-Oncology.


A 5-day program on Cardiovascular Safety Pharmacology and Cardio-Oncology consisting of theoretical lectures complemented by hands-on sessions in associated technologies. This course is a continuation of the EU-funded collaborative training network in safety pharmacology INSPIRE (, which in the past three years has built a training program benefiting from the academic, industrial, and clinical perspectives by exploring the latest technological capabilities to address emerging cardiovascular and cardio-oncology safety concerns.


The programme starts with a refresher on cardiovascular physiology and pathophysiology. Next, speakers from leading pharma companies will provide insight in the process of drug development and the importance of clinical safety. The regulatory landscape of drug development and safety evaluation will be elaborated, as well as a description of key methods implemented in Safety Pharmacology to identify adverse effects of drug candidates early on. A few case studies of failed drug candidates will be discussed as well. Further, clinical cases of drug-related cardiovascular complications presented by cardiologists will provide a wider perspective on the topic. More specifically, the discipline of cardio-oncology will be discussed in detail. With increasing survival rates of cancer patients, the long(er)-term effects of anticancer treatment (i.e. cardiac toxicity) are receiving more scrutiny. In this context, the programme will conclude with highlighting academic research to evaluate the detrimental effects of many anticancer drugs on endothelial cells. Endothelial cells are the inner lining of the vascular system and play a pivotal role in vascular physiology and pathophysiology. At the end of the programme, students will have gained a comprehensive view of the topic of cardiovascular (patho)physiology and how these mechanisms should be taken into account and screened for during drug development.


Successful completion of the summer school by attending all the lectures and participation in the oral examination can be awarded with 3 CREDITS according the European Credit Transfer System (ECTS).

To include the credits in the curriculum at the home institution, participants need an agreement with the responsible person at the home institution.

A certificate will be awarded at the end of the programme. All certificates of completion are issued as a micro-credential.

Type opleiding:
Kort- en langlopende opleidingen, Micro-credentials
Biomedische wetenschappen, Farmacie, Geneeskunde, Gezondheidswetenschappen
2024 - 2025
Theoretical courses

  • Dr. Elena Matsa, Director Discovery Technology at Ncardia
  • Lecturer TBD
  • Dr. Sylvain Bernasconi, Operations Manager & Product Director, Safety Pharmacology at NOTOCORD
  • Prof. Dr. Paul G.A. Volders, Professor of Genetic Cardiology and Principal Investigator at CARIM, School for Cardiovascular Diseases, Maastricht University Medical Centre+
Transferable skills
  • Prof. Dr. Robin De Cock, Professor of Innovation and Entrepreneurship and Director of the Master in Innovation & Entrepreneurship at the Antwerp Management School
  • Dr. Bruno Hoste, Consultant ZOOON
  • Dr. Bruno G.M. Hoste, Research Manager of Life Sciences at the Grant Office, Department of Research Affairs & Innovation, University of
  • Prof. Dr. Sabine Van Doorslaer, Professor at the Department of Chemistry, University of Antwerp, and member of the Flemish Commission for Scientific Integrity.

Stadscampus, University of Antwerp, Belgium

Meer informatie

Uw browser voldoet niet aan de minimale vereisten om deze website te bekijken. Onderstaande browsers zijn compatibel. Mocht je geen van deze browsers hebben, klik dan op het icoontje om de gewenste browser te downloaden.